Navigation Links
Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
Date:9/24/2007

PROPEL Enrollment Ahead of Schedule with Completion Expected Q2 2008

WESTMINSTER, Colo., Sept. 24 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the completion of pre-planned interim analyses of patient response and safety data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Results of the interim analysis of patient response data exceeded the pre-specified threshold for continuation of the trial, which required a minimum of four responses (complete or partial) out of the first 35 evaluable patients, as determined by independent oncology review. In addition, an independent Data Monitoring Committee (DMC) completed an interim analysis of the safety data from the first 35 evaluable patients and recommended that the trial continue per the protocol. No major safety concerns were identified by the DMC.

In accordance with the trial protocol, the DMC will conduct another interim analysis of safety data from the first 65 evaluable patients. The Company expects to report the outcome of the 65-patient safety analysis by the end of 2007. Additionally, the Company now expects to complete enrollment in the PROPEL trial in the second quarter of 2008.

"The outcomes of these interim analyses represent continued progress toward the completion of the PROPEL trial and an important milestone in the development of a potential new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma," said Pablo J. Cagnoni, M.D., Chief Medical Officer of Allos. "We are pleased with the progress of the PROPEL trial and look forward to completing enrollment in the second quarter
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
(Date:10/22/2014)...  Quest Diagnostics (NYSE: DGX ), the ... that its Board of Directors has elected Jeffrey M. ... 1, 2014. Including Dr. Leiden, the Board has 11 ... and CEO of Vertex Pharmaceuticals.   Dr. Leiden has ... in the pharmaceutical and biotechnology industries as well as ...
(Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
... Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical ... on women,s healthcare and pain management, announced today ... The round was led by Longitude Capital ... Point Capital. Other current investors that participated in ...
... Center Association, JWCH Institute and the County of Los ... Community Health Downtown Los Angeles, a state-of-the-art medical facility ... homeless and low-income people in and around Skid Row. ... Street, is expected to meet the healthcare needs of ...
Cached Medicine Technology:Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio 2Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually 2Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually 3
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... Pass, OR (PRWEB) October 22, 2014 ... Southern California’s fresh water supply runs dangerously low, Southern ... change. Southern Oregon’s rivers, despite the lowest mountain snow ... even in late summer and early autumn.* That was ... authors of the new book “Hiking Southern Oregon,” during ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Although there are only ... time for many people who have trouble finding time within their ... to exercise for long periods of time to get in shape. ... goals while on the go. , Change Up Your Commute ... to work to add some exercise into your daily routine. If ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... spike between 2008 and 2009, analysis finds , SATURDAY, ... appear to be on the rise, warns the American ... and baseball/softball are the main culprits. , The cautionary ... as they transpired between 2008 and 2009, based on ...
... drinkers were 39% less likely to get these malignancies ... help protect against head and neck cancers, a new ... the International Head and Neck Cancer Epidemiology consortium. They ... a day) were 39 percent less likely to develop ...
... is part of being a good dad, expert suggests , ... dads unwrap their new ties and other tokens of gratitude, ... kind of gift: a promise that they,ll watch their health, ... On average, men die younger than women and are more ...
... radiation not always ideal for many with low risk ... -- For patients with prostate cancer that has a ... "watchful waiting," may be a suitable treatment option, according ... of how (or whether) to treat localized prostate cancer ...
... ... ... Technologies , the leading independent provider of search software integration services announced today an ... for the Folio and NXT professional publishing products. The Folio product family includes Folio ...
... Recent research has shown increase in sexual satisfaction, if ... A U.S. Food and Drug Administration advisory panel on ... the "female Viagra" for premenopausal women with a diminished ... to the antidepressant family and affects serotonin and other ...
Cached Medicine News:Health News:Bump in Head Injury Numbers Linked to Summer Play 2Health News:On Father's Day, Give Dad Gift of Health 2Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 3
... Microvolume technology , The ADVIA 1650 has ... as 2 L/test), reagent consumption (as low ... L/hour) - thus maximizing management efficiency. , ... cycle and system throughput of up to ...
... and controls interchangeable with other Roche/Hitachi ... training costs. Consistent patient results throughout ... handling. 70 positions for routine, STAT ... volumes. Intermix sample types. Intermix 5 ...
With the sample processing core unit and intelligent process management, combines a wide variety of analytical modules to enable full consolidation of clinical chemistry and immunochemistry....
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
Medicine Products: